M
Masatoshi Nakajima
Researcher at Stanford University
Publications - 12
Citations - 3290
Masatoshi Nakajima is an academic researcher from Stanford University. The author has contributed to research in topics: 5-HT5A receptor & Angiotensin II. The author has an hindex of 11, co-authored 12 publications receiving 3261 citations. Previous affiliations of Masatoshi Nakajima include Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene
H. E. Von Der Leyen,Gary H. Gibbons,Ryuichi Morishita,Neil P. Lewis,Lunan Zhang,Masatoshi Nakajima,Yasufumi Kaneda,John P. Cooke,Victor J. Dzau +8 more
TL;DR: Direct evidence is provided that NO is an endogenous inhibitor of vascular lesion formation in vivo (by inhibiting smooth muscle cell proliferation and migration) and the possibility of ec-NOS transfection as a potential therapeutic approach to treat neointimal hyperplasia is suggested.
Journal ArticleDOI
Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors.
Masashi Mukoyama,Masatoshi Nakajima,Masatsugu Horiuchi,Hiroyuki Sasamura,Richard E. Pratt,Victor J. Dzau +5 more
TL;DR: In this article, a rat fetus expression library was used to clone a 363-amino acid protein with pharmacological specificity, tissue distribution, and developmental pattern of the AT2 receptor with 34% identical in sequence to the AT1 receptor, sharing a seven-transmembrane domain topology.
Journal ArticleDOI
The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer
Masatoshi Nakajima,Howard G. Hutchinson,Masahiko Fujinaga,Wataru Hayashida,Ryuichi Morishita,Lunan Zhang,Masatsugu Horiuchi,Richard E. Pratt,Victor J. Dzau +8 more
TL;DR: Results suggest that the AT2 receptor exerts an antiproliferative effect, counteracting the growth action of AT1 receptor.
Journal ArticleDOI
Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia
Ryuichi Morishita,Gary H. Gibbons,Kristin E. Ellison,Masatoshi Nakajima,Lunan Zhang,Yasufumi Kaneda,Toshio Ogihara,Victor J. Dzau +7 more
TL;DR: It is documents that a single intraluminal molecular delivery of combined cdc2 kinase and PCNA antisense ODNs results in a sustained inhibition of neointima formation in the rat carotid balloon-injury model.
Journal ArticleDOI
Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.
Ryuichi Morishita,Gary H. Gibbons,Kristin E. Ellison,Masatoshi Nakajima,H. E. Von Der Leyen,Lunan Zhang,Yasufumi Kaneda,Toshio Ogihara,Victor J. Dzau +8 more
TL;DR: Results demonstrate that a single intraluminal administration of antisense ODN directed to cell cycle regulatory genes (e.g., cdk 2 kinase) using the HVJ method can result in a sustained inhibition of neointima formation after balloon angioplasty in rat carotid injury model.